Key Takeaways
- Record quarter, Ethiopia restarting: Q4 FY23 operating revenue grew 35.12% YoY, the highest ever quarterly growth, while the Ethiopian plant resumed operations after a nine-month shutdown due to internal conflict.
- Ethiopia is the swing factor for FY24: With the factory running again, a government tender floated, and a forex proposal under review, management expects a robust FY24 and an even stronger FY25, though forex resolution remains a condition.
- Injectable capacity expansion underway: The Khopoli project has been conceptualized because management sees existing injectable contract manufacturing capacity hitting its limit within 1–2 years, with land acquired and bank sanctions in place.
- Margins are a hope, not a plan: Management is "striving" for margin improvement but offered no quantified path, asking investors to "keep our fingers crossed."
- What to watch next quarter: Whether the Ethiopian government's forex announcement materializes in July–August 2023, the pace of the plant's shift ramp-up, and any visibility on the Khopoli capacity figures management deferred.
Ethiopia: The Restart and the Forex Gate
- Factory reopened, losses behind: The plant was closed for nine months of FY23 due to internal fighting, which settled approximately two months before the call; operations have been running for the last 1.5 months, and the associated preliminary expenses and losses should now cease.
- Government tender in play: Ethiopia floated a Cephalosporin tender 15–20 days before the call; the company intervened to pause it until a forex mechanism was agreed, and the government has accepted in principle to provide foreign exchange for imported materials.
- Forex proposal submitted: A formal proposal requests that government tender payments be made in US dollars instead of the local Birr, which would unlock both imports and local supply; management expects a go-ahead "in very few months this year."
- Export registrations progressing: Files have been submitted in Sudan, Uganda, Kenya, Tanzania and Nigeria, and inspection has been triggered for these four to five countries; product registrations are expected "in a year or two years."
- Shift ramp-up contingent on government contracts: The plant currently runs one shift; when government contracts kick in, it will run a minimum of two shifts, and sustaining the private market may require a third.
- WHO Geneva inspection triggered: An inspection of the Ethiopian plant was triggered 15–20 days before the call, and a mock audit was successfully completed; EU approvals are also being pursued to open procurement from UN agencies under a "produce in Africa, sell in Africa" strategy.
Mukund Mehta: "First, there was internal fighting going on for 1.5 year, which has settled just two months before. ... But everything settled down. And from 1.5 month, everything is working now."
Ethiopia: The Margin and Market Structure
- Pricing power from sole manufacturing: Kilitch is the only manufacturer of these products in Ethiopia, and management stated there is "no question of margin" because the government is supportive and the company can sell at any cost.
- Private market only for now: All visible Ethiopian sales are from the private market; no government tender supply has occurred because the government pays in Birr, which creates challenges in obtaining US dollars, and the prices offered are not suitable without a forex provision.
- Banking reform tailwind: Ethiopia allowed two Kenyan banks to start operating last year, marking a change in the previously closed economy; management expects a broader economic opening announcement in July–August 2023, around Ethiopia's fiscal year-end.
Mukund Mehta: "There is no question of margin as we are the only manufacturer and government is supporting in all the ways. So I don't see, I don't say, no question of margin arises. You have goods, you sell at any cost, no one is saying."
Injectable Capacity and the Khopoli Project
- Capacity ceiling approaching: Management feels that within the next 1–1.5 years, or a maximum of two years, additional injectable capacity will be required, driven by contract manufacturing for Indian pharma companies like Intas and Indoco.
- Khopoli project status: Land has been acquired, non-agricultural conversion is done, the boundary is set, and planning is completed; construction will be pushed after the rainy season, with the factory expected to start producing from March 2025 onwards.
- Funding secured: Bank sanctions have been obtained to fund the Khopoli project.
- Utilization confidence: Management stated that getting work for the unit "will not be a daunting task," citing current customers' 8% to 12% year-on-year growth trends and a foreseeable demand-supply gap.
- Capacity figures deferred: Management did not provide current injectable capacity or the Khopoli plant's capacity on the call, stating they would consolidate figures across dosage forms (ampules, vials, dry powder injectables) and "come back to you on this."
Bhavin Mehta: "...looking forward, we feel that next one year, 1.5 year or maximum two years, we'll be in, requiring additional capacity. So because of which, the Khopoli project has been conceptualized..."
Domestic and Export Business
- Domestic growth driver: The effervescent division is performing very well, and management expects to do "much more better and better" in FY24, though it declined to commit specific figures.
- Double-digit growth expectation: Management expects double-digit year-on-year domestic growth, contingent on the government maintaining or increasing GDP spend on healthcare.
- Export commission expense rose: The INR 4 crores higher export commission expense versus last year reflects larger commissions relative to registration charges, plus increased fixed expenses, commissions, and traveling costs for country managers.
- Bhiwandi land held: The company will monetize its land asset "at the right moment" but is currently fully focused on pharma capex and sustained growth; the approximate value was not disclosed on the call.
UN Agency and Africa Strategy
- "Produce in Africa, sell in Africa": Management is pursuing WHO Geneva and EU approvals for the Ethiopian factory to open procurement from UN agencies, aiming to change the pattern of African governments buying from outside the continent.
- Timeline: This initiative is expected to fructify "in a year or two."
- Competitive positioning: Management stated that Kilitch has one of the biggest capacity setups in Ethiopia and is well placed to serve the African market from within Africa, a concept "well bought by all the UN agencies."
Bhavin Mehta: "This concept of their buying from outside Africa, we wish to change. Since, we are one of the biggest capacities in terms of setup in Ethiopia and we are in Africa. So the concept is well bought by all the UN agencies and we are following the pathway by which, we produce in Africa and where we sell in Africa."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Ethiopia forex resolution | Government announcement on economic opening expected | July–August 2023 |
| Ethiopia government tender supply | Go-ahead on US-dollar payment proposal expected | "Very few months this year" |
| Ethiopia export registrations | Products registered in seven to eight targeted countries | "In a year or two years" |
| Khopoli plant production start | Factory to begin producing | March 2025 onwards |
| UN agency procurement access | WHO Geneva and EU approvals for Ethiopia factory | "In a year or two" |
| Domestic growth | Double-digit YoY growth | Contingent on government healthcare spend |
Key Metrics
| Metric | Q4 FY23 |
|---|---|
| Standalone operating revenue | ₹43.28 cr, growth of 35.12% YoY |
| Standalone EBITDA | ₹8.12 cr, growth of 71.31% YoY |
| Standalone EBITDA margin | 18.76%, improved from 14.11% YoY |
| Standalone PAT | ₹5.13 cr, growth of 69.87% YoY |
| Standalone EPS | ₹3.29 per share, up from ₹1.94 per share YoY |
| FY23 standalone operating revenue | ₹117.78 cr, increase of 12% YoY |
| FY23 standalone EBITDA | ₹21.74 cr, growth of 39.91% YoY |
| FY23 standalone EBITDA margin | 18.8%, improved from 14.80% YoY |
| FY23 standalone PAT | ₹15.72 cr, growth of 49.29% YoY |
| FY23 standalone EPS | ₹10.09 per share, up from ₹6.76 per share YoY |
| Export commission and registration expense (Q4) | ₹5.4 cr |
| Export commission and registration expense (FY23) | ₹11.42 cr, more than double the previous year's ~₹5.48 cr |
| Export commission rate | 8% to 15% of sales, depending on the market |
| Ethiopian Cephalosporin plant capacity | ~1.6–1.7 cr vials per year |
| Ethiopian government Cephalosporin requirement | 2.5 cr vials per year |
| Products registered across the world | Over 600 |
| Products under registration process | 450 plus |
| African portfolio | 350 products across 26 countries |
| Khopoli Greenfield project capex | More than ₹100 cr |
| Khopoli plant expected production start | March '25 onwards |
| Ethiopia JV structure | 67% Kilitch, 33% local distributor |
| Ethiopia tax holiday | 4 years income tax benefit, started 21 July '21, due till July '25 |
| Cephalosporin private market realization (Ethiopia) | 30–35 birr |
| Khopoli plant funding | Sanctions from banks obtained, external loan |